Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Natco Pharma shares jump 4% amid weak broader markets; here' why
Shares of Natco Pharma Ltd surged nearly 4.35 per cent to Rs 1,413.45 on Monday, commanding a total market capitalization close to Rs 25,000 crore.
Here's why Natco Pharma share price gained over 4% on October 7; details
Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)
Natco Pharma shares rise 4% on settlement order in US patent case over generic Ozempic
The strong up move was seen in the stock price with the scrip touching the day's high of Rs 1,408.70 per share on the NSE, rising 4 percent.
Natco Pharma shares gain after settlement in US patent litigation on generic Ozempic
Mylan Pharmaceuticals Inc and Novo Nordisk, the original patent holder for Ozempic, have reached a settlement in the US patent litigation concerning the drug, Natco Pharma informed the stock exchanges in a filing.
Natco shares gain after antidiabetic drug partner Mylan, Novo Nordisk settle patent litigation
Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.
Natco Pharma soars after Mylan settles Ozempic patent dispute
Natco Pharma rose 3.39% to Rs 1400.60 after the company announced a settlement in the U.S. patent litigation for generic Ozempic.
Natco Pharma settles US patent case over generic Ozempic
According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.
Natco Pharma partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US
Hyderabad: NATCO Pharma Limited has announced that its partner Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the U.S. patent litigation related to generic
Mylan Settles Patent Suit with Novo Nordisk over Generic Ozempic
Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement in the US over a patent infringement lawsuit regarding generic Ozempic, a drug used for blood sugar and weight loss.
Mylan settles patent litigation with Novo Nordisk over generic Ozempic in United States
According to a report by news agency PTI, NATCO and Mylan have partnered for the development of generic Ozempic (Semaglutide) products, the company said in a regulatory filing. Ozempic is a prescription medication patented by Novo Nordisk.
FiercePharma
11h
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...
devdiscourse
19h
Settlement Reached in Ozempic Patent Battle
NATCO Pharma Ltd announced that Mylan Pharmaceuticals Inc has settled a lawsuit with Novo Nordisk in the US concerning the ...
12h
on MSN
Stock market update: Nifty Pharma index falls 0.51%
The Nifty Pharma index closed on a negative note on Monday. Shares of Natco Pharma Ltd.(up 3.53 per cent), Glenmark ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Mexican mayor assassinated
Ring ceremony canceled
Milton becomes Category 5
American sentenced in RU
Ranger dies during rescue
Musk's X appeal rejected
Vanderbilt, Arkansas fined
Supreme Court rejects bid
King named grand marshal
TX emergency abortion case
Hamas strikes Tel Aviv
Another top aide resigns
Faces assault, drug charges
Ukraine strikes RU oil hub
Mark Oct 7 anniversary
R. Kelly's appeal declined
Record military aid to Israel
SCOTUS new term begins
Names new school board
North Dakota wildfires
Launches asteroid probe
NC voting changes
GA abortion ban reinstated
US antitrust case advances
Hamas backers sanctioned
IVF clinic's appeal rejected
Related topics
Ozempic
Mylan
Feedback